title: Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.
abstract: The renin-angiotensin-aldosterone system (RAAS) is a key mediator of blood pressure (BP) and volume regulation in both normotensive and hypertensive persons. Stimulation of RAAS also contributes to hypertension-related target organ damage. The renin-angiotensinogen reaction is the first and rate-limiting step in the generation of angiotensin II (Ang II) and has been a target of antihypertensive drug development for decades. Aliskiren is the first in a new class of orally effective direct renin inhibitors (DRIs) and is approved for the treatment of hypertension in humans. It effectively reduces BP in the general population of hypertensive patients and has a tolerability and safety profile similar to placebo. Aliskiren has favorable effects on vascular inflammation and remodeling, on neurohumoral mediators of various forms of cardiovascular disease, including heart failure, and on proteinuria in diabetic patients. Additional outcome trials are needed to establish the role of this novel class of antihypertensive medication in preventing cardiovascular disease morbidity and mortality.
authors.affiliation: Endocrine Hypertension Research Centre and Clinical Centre of Research Excellence in Cardiovascular Disease and Metabolic Disorders, University of Queensland School of Medicine, Greenslopes Princess Alexandra Hospitals, Brisbane, QLD, Australia;
authors.forename: Eduardo
authors.initials: E
authors.lastname: Pimenta
authors.forename: Suzanne
authors.initials: S
authors.lastname: Oparil
references.citation: Am J Hypertens. 2007 May;20(5):587-97
references.pmid: 17485026
references.citation: Circulation. 2008 Jun 24;117(25):3199-205
references.pmid: 18559696
references.citation: J Am Coll Cardiol. 2008 Feb 5;51(5):519-28
references.pmid: 18237679
references.citation: Lancet. 2007 Jul 21;370(9583):221-229
references.pmid: 17658393
references.citation: J Hypertens. 2007 Sep;25(9):1775-82
references.pmid: 17762637
references.citation: J Am Coll Cardiol. 1996 Oct;28(4):803-12
references.pmid: 8837552
references.citation: Kidney Int. 1994 Dec;46(6):1522-4
references.pmid: 7699995
references.citation: Circ Heart Fail. 2008 May;1(1):17-24
references.pmid: 19808266
references.citation: J Renin Angiotensin Aldosterone Syst. 2008 Sep;9(3):163-75
references.pmid: 18957387
references.citation: Circulation. 2009 Feb 3;119(4):530-7
references.pmid: 19153265
references.citation: Hypertension. 2001 Apr;37(4):1047-52
references.pmid: 11304501
references.citation: J Clin Invest. 1996 Nov 1;98(9):1966-70
references.pmid: 8903314
references.citation: Hypertension. 2009 Mar;53(3):516-23
references.pmid: 19171793
references.citation: J Renin Angiotensin Aldosterone Syst. 2007 Dec;8(4):190-8
references.pmid: 18205098
references.citation: Blood Press Suppl. 2008 Dec;2:31-40
references.pmid: 19203020
references.citation: Circulation. 2008 Aug 12;118(7):773-84
references.pmid: 18695203
references.citation: J Hypertens. 2008 Mar;26(3):589-99
references.pmid: 18300872
references.citation: Nephrol Dial Transplant. 2009 May;24(5):1663-71
references.pmid: 19145003
references.citation: J Hypertens. 2007 Jan;25(1):217-26
references.pmid: 17143194
references.citation: Hypertension. 2002 Jan;39(1):E1-8
references.pmid: 11799102
references.citation: Curr Opin Nephrol Hypertens. 2008 Sep;17(5):484-90
references.pmid: 18695389
references.citation: N Engl J Med. 2008 Jun 5;358(23):2433-46
references.pmid: 18525041
references.citation: Hypertension. 2007 May;49(5):1047-55
references.pmid: 17353513
references.citation: Hypertension. 2009 Jun;53(6):1062-9
references.pmid: 19364992
references.citation: Cardiol Clin. 2008 Nov;26(4):527-35
references.pmid: 18929229
references.citation: Am J Hypertens. 2009 Jan;22(1):112-21
references.pmid: 18802434
references.citation: Circulation. 2009 Jan 27;119(3):417-25
references.pmid: 19139391
references.citation: J Hypertens. 1998 Jun;16(6):853-62
references.pmid: 9663926